Clinical Trial Update: An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

An extension Phase 3 study evaluating the long-term safety and potential symptom improvement of litifilimab (BIIB059) in adults with systemic lupus erythematosu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Litifilimab (litifilimab)

Snippet

Sponsor: Biogen | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 3 | Status: ENROLLING_BY_INVITATION